Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics

Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics

Series BUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$89.0Msum of rounds with a disclosed amount only
Named investors
6
Financing history
1 rounds
  1. Mar 26, 2026
    Series B · $89.0M (disclosed)
    Foresite Capital (lead) via Cindy XiongQuan Capital Management, LLC (participant)HanKang Capital (participant)RA Capital Management, LP (participant)LAV (lead)Logos Capital (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials”
Investors on record
6 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Mar 26, 2026
    Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics announced Series B of $89,000,000, led by LAV, Foresite Capital
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company